Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Rapid emergence of drug-resistant viral mutants poses a significant challenge to effective treatment of viral infectious diseases and to the development of antiviral therapies. A better strategy is needed for developing a new class of antiviral drugs that minimize the emergence of drug-resistance and have a broad-spectrum antiviral efficacy.Like antibiotics for treatment of bacterial diseases, most, if not all, of today’s antiviral drugs are designed to target a specific virus-encoded gene or function. For examples, Zidovudine (AZT) is a nucleoside analog reverse transcriptase inhibitor that specifically inhibits the reverse transcriptase of retroviruses such as human immunodeficiency virus (HIV); Atazanavir (Reyataz) is a protease inhibitor that is also used to treat HIV infection; Osteltamivir (Tamiflu) is an inhibitor of the neuraminidase of influenza viruses.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi